Early but strong data suggest "we might be onto something" with self-injected APL-2 for the blood disease paroxysmal nocturnal hemoglobinuria (PNH), Apellis Pharmaceuticals Inc. CEO Cedric Francois told BioWorld Today, as the company disclosed positive interim results from two ongoing phase Ib open-label, dose-escalation trials.